Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant variant COVID-19 vaccine (Sf9 cell)
- Development stage
- Unknown
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A recombinant, protein-based nanoparticle COVID-19 vaccine produced using the baculovirus expression vector system in Sf9 insect cells. The process involves inserting the gene encoding a SARS-CoV-2 spike protein variant into a baculovirus, which is then used to infect Sf9 cells derived from *Spodoptera frugiperda* ovarian tissue. Inside these cells, large quantities of the spike protein are produced and harvested. The purified proteins are assembled into nanoparticles and typically formulated with an adjuvant such as Matrix-M to enhance immune response. This platform allows for rapid adaptation to new variants by updating the genetic sequence used for production[1][2][4]. The primary indication is prevention of COVID-19 caused by specific SARS-CoV-2 variants.
- Other names
- recombinant protein-based COVID-19 vaccine (Sf9 cell)SARS-CoV-2 spike protein nanoparticle vaccine (Sf9 cell)insect-cell based recombinant COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant variant COVID-19 vaccine (Sf9 cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant variant COVID-19 vaccine (Sf9 cell).